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Abstract: 
A collaborative multidisciplinary research project is described in which new natural product anticancer drug 
leads are obtained from a diverse group of organisms, constituted by tropical plants, aquatic cyanobacteria, and 
filamentous fungi. Information is provided on how these organisms are collected and processed. The types of 
bioassays are indicated in which crude extracts of these acquisitions are tested. Progress made in the isolation of 
lead bioactive secondary metabolites from three tropical plants is discussed.  
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INTRODUCTION  
Cancer is responsible for about one in every four deaths in the United States and is therefore a major public 
health burden. The American Cancer Society projects that in 2008, there will be over 1.4 million new cases of 
invasive cancer diagnosed and over 565 000 deaths from cancer, or more than 1500 deaths each day. The major 
cancer mortalities in the United States result from cancers of the lung and bronchus, prostate, and colon and 
rectum in men, and of the lung and bronchus, breast, and colon and rectum in women [1]. Developing countries 
are being increasingly afflicted with cancer, as their populations live longer and make negative lifestyle changes 
associated with increased cancer risk [2,3]. Accordingly, the threat of cancer will be of major concern for the 
foreseeable future for those in both developed and developing countries. Cancer chemotherapy is an important 
alternative to surgery and radiation to treat successfully some types of solid tumors, lymphomas, and leukemias, 
and many clinically approved cytotoxic and antiproliferative anticancer drugs are available, both of synthetic 
and natural product (microbial and plant) origin [4,5]. However, much progress needs to be made to overcome 
the problems of resistance to and toxicity of existing cancer chemotherapeutic agents [4,5]. It is expected that in 
the future, anticancer drug discovery will need to focus on mechanism-based agents that act on specific 
molecular targets associated with the etiology of cancer [6].  
Natural product compounds have substantial structural diversity and frequently afford new mechanisms of 
biological activity. As a result, natural products are used widely in cancer chemotherapy [7]. Accordingly, there 
is a continued interest in the investigation of extracts of microorganisms, terrestrial plants, and marine life forms 
to search for further compounds of this type [7-10]. In a recent analysis of the antineoplastic agents marketed in 
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western countries and Japan, it was revealed that of 155 compounds in total ever introduced since the 1940s, 
47.1 % were either unmodified natural products (25 compounds, 16.1 %) or semi-synthetic derivatives of 
natural products (48 compounds, 31.0 %) [9]. Natural product anticancer agents have been discovered and 
developed primarily by the pharmaceutical industry, but important contributions have been made by academic, 
governmental, and private research laboratories. In a recent major volume on promising compounds from nature 
as anticancer agents, there were 6 major classes from plants, 7 from marine organisms, and 10 from microbes, 
indicating that all types of organisms should be accessed to maximize the likelihood of discovering effective 
new cancer drugs [7]. Natural products are recognized as occupying a different region of "chemical space" than 
typical synthetic compounds [e.g., 11-13] and are an excellent source of novel chiral structures for synthetic and 
combinatorial chemistry modification for drug development [14].  
In this short review, we will describe a new multi-institutional collaborative project funded by the U.S. National 
Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, through the "program project" 
(P01) mechanism. This is a successor to a previous "National Cooperative Drug Discovery Groups" (NCDDG) 
project (U01/U19 mechanism), also funded by NCI, NIH, and involves the same four partners, namely, two 
academic groups (The Ohio State University and the University of Illinois at Chicago), a private, nonprofit 
research institute (Research Triangle Institute, North Carolina), and an industrial partner (Bristol-Myers Squibb, 
Pharmaceutical Research Institute, Princeton, New Jersey). In this new project, however, there is now the 
participation of a biotechnology company, Mycosynthetix, Inc. (Hillsborough, North Carolina). Descriptions of 
our collaborative work on the former NCDDG project have been published previously [15,16]. In our new 
program project, in addition to investigating tropical plants, we are also targeting aquatic cyanobacteria and 
filamentous fungi for the discovery of potential new anticancer agents. In the following paragraphs we will 
briefly review progress made by others previously in terms of anticancer drug discovery among these three 
types of organisms.  
For over a decade, members of four major groups of plant-derived anticancer agents have been available in the 
United States and elsewhere, including the vinca (Catharanthus) bisindole alkaloids, the epipodophyllotoxin 
analogs, the taxanes, and the camptothecins [4,5,7]. Moreover, the anticancer clinical development of over 10 
further derivatives of paclitaxel and camptothecin is currently taking place [7,10,17]. Several other plant-
derived substances show potential for future use in cancer chemotherapy. A number of these compounds are 
already in clinical trials in the United States and/or in other countries. The compound perhaps closest to market 
approval is combretastatin A4 phosphate, a plant-derived stilbenoid with antimitotic and antiangiogenic 
activities [7,10]. Butler has recently reviewed the current oncology clinical trial status of several additional 
substances of plant origin, inclusive of the alkaloid, homoharringtonine; the benzopyran, phenoxodiol (a 
synthetic derivative of the isoflavone, diadzein); the diterpene ester, ingenol 3-O-angelate; and the isoflavone, 
genistein [10].  
Cyanobacteria (blue-green algae) have been identified as a promising source of novel bioactive metabolites [18-
22]. Prominent experimental anticancer agents include the cryptophycins from terrestrial blue-green algae 
[7,23], and the dolastatins, originally derived from a seahare, Dolabella auricularia, but now found in certain 
marine cyanobacteria, and therefore thought to be of dietary origin [10,24]. Of these, dolastatins 10 and 15 are 
currently in oncology clinical trials [10]. A screening pro- gram on cultured cyanobacteria demonstrated that 
antineoplastic compounds are distributed widely among cyanophytes [25]. The rate of rediscovery of known 
bioactive compounds, however, is known to be significantly lower among the cyanobacteria than other 
microbial sources with similar hit rates such as actinomycetes. Despite this, cyanobacteria are relatively 
unexplored as potential anticancer agents, particularly from aquatic sources.  
A number of fungal compounds have been investigated for anticancer activity [7,26], including brefeldin A 
[27], cytochalasin E [28], gliotoxin [29], illudin S [30], irofulven [10,31], the leptomycins [7], palmarumycin 
CP1 [7], terrecyclic acid A [32], and wortmannin [33]. Most of these structurally diverse compounds were 
discovered 30 years or more ago, and at some later time shown to have potential anticancer activity. Irofulven, a 
DNA synthesis inhibitor based on the lead compound, illudin S, is now in late-phase oncology clinical trials 
[10]. Recently, lodamin, a new angiogenesis inhibitor based on TNP-470, itself related to cytochalasin E and 
originally isolated from Aspergillus fumigatus fresenius and discovered through serendipity in Folkman's 
laboratory [34] and then modified using nanotechnology, has shown promise in murine models of a number of 
cancer types [35].  
COLLECTION AND PROCESSING OF ORGANISMS  
A continued search for anticancer agents from tropical plants, aquatic cyanobacteria, and filamentous fungi 
should pay dividends, both in terms of the potential discovery of further examples of antitumor agents of natural 
origin and the favorable prospects of generating specific molecular probes germane to the biology of cancer. 
The strategies being used to collect and process these three basic types of organisms in our program project will 
be discussed briefly in turn.  
In our former NCDDG project, the entire focus was on the discovery of plant-derived anticancer agents from 
understudied endemic species of tropical rainforest plants [15,16]. This is still a valid approach, since humid 
tropical forests sustain considerable biodiversity, and in some areas more tree species may be found in a 0.5 
[km.sup.2] area than in all of North America [36]. Moreover, some 25 biodiversity "hot spots" occur (44 % of 
all vascular species in 1.4 % of the earth's land surface) [37], and it has been estimated that of the total number 
of higher plant species on earth (310 000-422 000), about 120 000 are found in biodiversity "hot spots" that are 
under threat from massive habitat loss [38]. It has been calculated that as many as 60 000 species of flowering 
plants will have become extinct before the year 2050 [38]. Furthermore, so far as the tropical rainforests are 
concerned, they occupy only 7-8 % of the land surface of the earth, but offer a disproportionate opportunity for 
the discovery of structurally novel, pharmacologically active substances [39]. This has been attributed to 
elevated temperatures, high humidity and high species density, and a continuous growing season, resulting in 
the accumulation of specialized secondary metabolites by rainforest species as defensive mechanisms against 
predators and parasites, and as pollination attractants [40]. By concentrating on tropical rainforest plants rather 
than temperate species, it is hypothesized that greater chemical diversity will result.  
The approaches taken in plant collection have been discussed previously, inclusive of the development of 
benefit-sharing agreements, the use of the NAPRALERT database to select under-investigated endemic plants 
for subsequent laboratory study, and the types and numbers of plant parts collected per species [15,16]. A 
retrospective study has been conducted in which plant profiles (i.e., country of collection, taxonomy, and plant 
part) for acquisitions obtained for our former NCDDG project were compared with the resultant cytotoxic 
activity of extracts prepared from these samples, when evaluated against a panel of human tumor cell lines [41]. 
Altogether, over 2600 plant acquisitions were made over an approximately 15-year period. On average, the 
most potently cytotoxic extracts were prepared from plants collected in Ecuador, out of six major tropical and 
subtropical countries and regions where plant collections were made. Of over 150 plant families collected, the 
most promising cytotoxic activities were from plants in the Clusiaceae, Elaeocarpaceae, Meliaceae, and 
Rutaceae. Particularly active genera from the over 650 represented were Aglaia, Casearia, Exostema, Mallotus, 
and Trichosanthus. In general, it was found that roots and other below-ground organs afforded more potently 
cytotoxic extracts than extracts prepared from above-ground plant parts [41]. For the ongoing program project 
work, it is proposed to supplement our existing plant holdings with new primary collections from Indonesia, 
Vietnam, and other countries. We are continuing to utilize a simple plant solvent extraction scheme, which has 
proved to be reproducible as used over the last decade [15,16,42]. Typically, only the organic-soluble extract (a 
chloroform extract treated with sodium chloride) for each plant acquisition is submitted for initial biological 
screening, with the remaining fractions (hexane wash and aqueous residue) retained in case of need. A de-
replication method is applied to plant extracts to avoid the re-isolation of previously known cytotoxic 
compounds [43].  
In this collaborative work, aquatic cyanobacteria are being collected in part in the field, with some samples 
obtained from commercial sources. The latter group is represented by the Culture Collection of Algae at the 
University of Texas at Austin (UTEX), the Provasoli-Guillard National Center for the Culture of Marine 
Phytoplankton (CCMP), and the Culture Collection of Algae at the University of Gottingen (SAG). All 
taxonomic orders of cyanobacteria (viz., Chroococcales, Nostocales, Oscillatoriales, Pleurocapsales, and 
Stigonematales) are present in our culture collection, which currently consists of over 300 cyanobacterial 
strains. Obstacles in studying the bioactive secondary metabolites of cyanobacteria are the slow growth rate and 
low biomass yield of these organisms in culture. To overcome these limitations, we use the recently developed 
micro-analytical technique of segmented flow analysis (SFA) microcoil NMR [44] to reduce the amounts of 
pure material needed for structure elucidation to only ~50 [micro]g. This typical initial small amount of 
compound isolated enables us not only to determine its structure but also to measure the level of activity against 
selected molecular targets. It also significantly lowers the amount of starting biomass required, and we are able 
to perform most of our studies with a total fermentation volume of 4 L. Each strain is grown in two aerated 2.8 
L Fernbach flasks with 2 L media for a total fermentation volume of 4 L. The cells are harvested after 4-8 
weeks and separated by centrifugation. The freeze-dried biomass is subjected to extraction with methanol-
dichloromethane (1:1), with this organic extract then used for initial biological screening. Scale up and re-
isolation of larger amounts of a natural product of interest for further biological and chemical evaluation is 
performed according to our program needs.  
The program project has access to a library of over 55 000 filamentous fungi, housed at Mycosynthetix, Inc. 
Although acquisitions in this collection have been examined for drug leads for several different pharmaceutical 
and agrochemical applications in the past, this library has never been examined systematically as anticancer 
leads. It has been estimated that 1.5 million species of fungi exist in the world [45], and of these, only 70 000 
have been subjected to taxonomic studies. Hence, the vast majority of fungi have never been tested for any kind 
of biological activity, let alone subjected to chemical evaluation. The Mycosynthetix fungal collection was 
established over the past two decades and was collected in the form of mycelia, rather than simply as spores. 
These samples were isolated and preserved from targeted ecosystems from around the world, after obtaining the 
necessary permissions.  
Mycosynthetix has developed approaches to culturing fungi that supports the production of unusual metabolites, 
including the use of both liquid and solid media. In many instances, it has been observed that a particular 
metabolite is produced specifically under only one set of conditions. Diverse growth conditions are utilized to 
optimize the chances of discovering promising biological activity. This ability to culture and optimize the 
growth conditions of an organism presents a means to re-supply a large quantity of a promising lead compound. 
Prior to initial biological screening, fungal specimens are subjected to a two-stage culturing procedure, in both 
liquid seed and grain-based solid media. For initial biological testing, cultures are extracted with 1:1 
chloroform-methanol, with organic and aqueous partitions being produced, and the organic extract partitioned 
into 1:1 acetonitrile-hexane.  
BIOLOGICAL EVALUATION OF SAMPLES  
Once initial crude extracts are prepared from tropical plants, aquatic cyanobacteria, and filamentous fungi, they 
are subjected to evaluation in a battery of cell- and mechanism-based assays housed at the various locations 
where the laboratory work in our program project is carried out. Cytotoxicity assays using selected cancer cell 
lines are conducted at The Ohio State University [46], Research Triangle Institute [47], and Bristol-Myers 
Squibb [16], with a focus on selectivity of activity in each case. Some of the target-based assays that have been 
selected are the activation of nuclear factor-[kappa]B (NF-[kappa]B) [48] and of nuclear factor of activated T 
cells (NFAT) [49,50], as well as a mitochondrial transmembrane potential (MTP) assay [51], at The Ohio State 
University; modulation of EZH2 levels and activity at Research Triangle Institute [52,53], and inhibition of 
histone deacetylase [54,55] and the 20S proteasome [56,57] at the University of Illinois at Chicago. A key 
element of our group interaction is the prioritization of in vitro-active crude extracts for subsequent activity-
guided purification [15,16].  
In an earlier review on our collaborative work on anticancer agents from natural sources, a detailed account was 
given as to how the in vivo hollow fiber assay is used [16]. This method was developed at the U.S. National 
Cancer Institute (NCI) [58-60] and transferred to the University of Illinois at Chicago nearly 10 years ago [61]. 
In our hands, we have found this method to be a useful secondary assay to help determine if a given in vitro-
active compound is likely to be active in a traditional xenograft assay [61]. In the hollow fiber assay, human 
cancer cells are propagated within fibers that are implanted either intraperitoneally (ip) or subcutaneously (sc), 
and this is quite rapid and inexpensive, and may require only 25 mg of test compound for the total testing. For 
follow-up in vivo investigations, we have used the P388 murine lymphocytic leukemia model [62] and 
xenografts of human tumor cells implanted in immunodeficient mice [61,63,64], as performed according to 
standard protocols. Depending on compound potency, it may be necessary to consume up to 100 mg of pure 
compound in the requisite number of mice for this type of testing. It has been our experience that only a small 
percentage of compounds found to be active in initial in vitro assays have in vivo activity on subsequent 
biological testing.  
We have found the biological testing resources available through the NCI to be highly complementary to our 
research efforts. For example, the NCI 60-cell line panel provides data on potency and selectivity against 
various leukemias and solid types of cancer in cell culture [65,66], as well as useful information on mechanism 
of action through the COMPARE program (e.g., [67]). The RAID ("Rapid Access to Intervention 
Development") program provides resources leading to preclinical development of new anticancer agents [68], 
and we have accessed this mechanism of support in the past [16].  
PROGRAM PROJECT ORGANIZATION  
An organizational scheme of our program project research collaboration is shown in Fig. 1. This figure shows 
the locations of each project and core, and the major technical activities carried out. It is intended that the core 
components are highly integrated with all three of the main projects, with Projects 1-3 focused on the 
investigation of tropical plants, aquatic cyanobacteria, and filamentous fungi, respectively. The fungi are 
provided for this collaboration by Mycosynthetix, Inc. We have made use of the Natural Products Repository of 
the U.S. National Cancer Institute to obtain taxonomically authenticated extracts from selected geographical 
regions to help prioritize plant collections and recollections [68]. The technical expertise represented by the 
senior investigators enables all of the following specific aims to be achieved: collection and taxonomic 
authentication of organisms; development of intellectual property agreements in order to access organisms; 
initial solvent extraction of organisms; testing of extracts against a wide panel of cell-based and mechanism-
based primary in vitro assays; isolation and structure elucidation of in vitro-active principles of initial leads; de-
replication of bioactive extracts and chromatographic fractions for previously known bioactive compounds; 
testing of promising compounds in tumor growth inhibition assays; application of biostatistics for bioassays; 
pharmaceutical development of highly promising leads; overall project administration. The senior investigators 
of the project have face-to-face meetings in different locations three times a year, including an annual meeting 
in the presence of the program project External Advisory Board, comprised of Drs. John M. Cassady, O. 
Michael Colvin, Susan B. Horwitz, and G. Robert Pettit. The project receives input from the NCI Program 
Coordinator (Dr. Yali Fu). We are not aware of any other natural product anticancer drug discovery project that 
has previously been funded by the U.S. National Cancer Institute through the program project (P01) 
mechanism.  
EXAMPLES OF COMPOUNDS RECENTLY ISOLATED AND EVALUATED  
 
 
To exemplify compounds isolated in this collaboration in our ongoing work, compounds from three tropical 
plant leads that have shown some in vivo activity are briefly reviewed below. In each case, a valid benefits-
sharing agreement has been in place prior to plant collection. The examples have been chosen to complement 
those mentioned in the last review article on this project [16], and much progress has resulted from the 
significant interactions between the various groups in our consortial team. However, at this preliminary stage in 
our program project, work has not progressed sufficiently for examples of active compounds from 
cyanobacteria and filamentous fungi to be included herein.  
Alvaradoins E-N from Alvaradoa haitensis  
In 1999, four compounds in the "alvaradoin" series, alvaradoins A-D, were isolated and characterized from the 
aerial parts of Alvaradoa jamaicensis Benth., but these were not investigated for their potential anticancer 
activity [69]. In work carried out at Research Triangle Institute, bioactivity-directed fractionation of an extract 
of the leaves of Alvaradoa haitiensis Urb. (Picramniaceae), led to the isolation and structure elucidation of 10 
new anthracenone C-glycosides, alvaradoins E-N, in addition to the known compound, chrysophanol [70]. The 
plant was collected in the Dominican Republic, and the human oral epidermoid carcinoma (KB) cell line was 
used to monitor the chromatographic fractions for activity. Of these compounds, the pair of epimers, 
alvaradoins E (10S) (1; Fig. 2) and F (10R) (2; Fig. 2) were most highly cytotoxic (KB; [EC.sub.50] 0.050 [+ or 
-] 0.019 [micro]M and 0.065 [+ or -] 0.026 [micro]M, respectively), and approximately 10-fold more potent 
than any of the remaining alvaradoins isolated from A. haitensis leaves. Alvaradoin E (1), the most potently 
cytotoxic substance, was further evaluated in vivo in the P388 assay at Bristol-Myers Squibb where it showed 
modest antileukemic activity (125 % treatment/ control, T/C) at a dose of 0.2 mg/kg per intraperitoneal (ip) 
injection. When compound 2 (alvaradoin F) was evaluated in the same model, it showed less activity (115 % 
T/C) at a maximally tolerated dose of 0.4 mg/kg per ip injection [70]. Using the in vivo hollow fiber model at 
the University of Illinois at Chicago, alvaradoin E demonstrated significant growth inhibition at the ip site when 
tested with KB, LNCaP, and Col2 cells [71]. When alvarodoin E (1) was evaluated in the P388 model in which 
both the cancer cells and test compound were administered intravenously, the compound was found to be 
inactive [70], consistent with the results obtained for this compound in the hollow fiber assay, with the cells 
implanted subcutaneously [71].  
A series of experiments was then conducted at the University of Illinois at Chicago to demonstrate that the 
cytotoxicity of alvaradoin E (1) was mediated through apoptosis. Treatment of prostate cancer cells (LNCaP) 
for 24 h or less at concentrations ranging from 70 nM to 1.12 [micro]M caused early signs of apoptosis 
including chromatin condensation (as judged by DAPI analysis) and mitochondrial membrane depolarization 
(as shown by DiOC6 uptake). Certain late events in apoptosis were also evaluated in HL-60 human 
promyelocytic leukemia cells by flow cytometry using an annexin V-FITC assay, which assesses cell viability, 
as well as the TUNEL assay, to measure DNA cleavage. Within 36 h of exposure, compound 1 was observed to 
significantly decrease (8.6-fold) cell viability and to increase (10-fold) DNA cleavage [71].  
Aculeatins A and B from Amomum aculeatum  
In 2000 and 2001, Heilmann and Sticher and coworkers at ETH-Zurich reported on several compounds of the 
1,7-dioxadispiro[5.1.5.2]pentadecane type from the plant, Amomum aculeatum Roxb. (Zingiberaceae), with 
cytotoxic, antimicrobial, and antiprotozoal activities, including the parent compounds aculeatins A and B 
[72,73]. As a result of subsequent enantioselective syntheses by the Marco group, the absolute configurations of 
these two compounds were established as 3 (Fig. 2) and 4 (Fig. 2), respectively [74,75]. Owing to the unusual 
chemotype exhibited by aculeatins A and B, we felt it worthwhile to more thoroughly investigate this 
compound class for potential anticancer activity.  
 
 
In an initial investigation carried out at The Ohio State University, four new compounds with a C-9 hydroxy 
group, aculeatols A-D, were isolated from the leaves of A. aculeatum collected in Indonesia, along with 
aculeatins A (3) and B (4) [76]. Also obtained in this investigation was an acyclic compound, 5R-hydroxy-1-(4-
hydroxyphenyl)-eicosan-3-one, purified from the rachis of the plant, which is a possible precursor for 
compounds 3 and 4 [76]. Additional phytochemical work on this same plant led to the isolation of compounds 
inclusive of aculeatol E (5, Fig. 2) and amomol A (6, Fig. 2). In the latter compound, the cyclohexane ring is 
cleaved, and the C-12 stereochemistry was established as R by the Mosher ester method, but the C-2 
configuration was unresolved [77]. Since a few hundred milligrams of aculeatin A (3) were purified, several 
semi-synthetic esters and other derivatives of this compound were generated. However, it was found that 
aculeatin A was the most potently cytotoxic dioxadispiroketal derivative for a small panel of human cancer cell 
lines (Lu1, lung; LNCaP, prostate; MCF-7, breast) when compared with the various naturally occurring and 
semi-synthetic analogs obtained [77].  
Accordingly, aculeatin A (3) was selected for testing in the in vivo hollow fiber assay at the University of 
Illinois at Chicago. When evaluated against three cancer cells in hollow fibers (Lu1, LNCaP, and MCF-7), the 
compound inhibited the growth only of MCF-7 cells by 10-60 % at the dose range 6.25-50 mg/kg body weight, 
when administered at the intraperitoneal site [77]. However, when this compound was tested in two in vivo 
models at Bristol-Myers Squibb (murine P388 lymphocytic leukemia and human A2780 ovarian carcinoma 
murine xenograft models), it was not deemed to be active [77]. Owing to the activity shown in the hollow fiber 
assay, it may be worthwhile to conduct a xenograft study on aculeatin A (3) using the MCF-7 cell line. 
Recently, work by Wong et al. [78] has led to the synthesis of several novel complex polyspirocyclic analogs of 
aculeatin A with enhanced antimalarial activity compared with the parent compound. While not the primary 
focus of the work, mammalian cell toxicity was determined using K562 human chronic myelogenous leukemic 
cells, in order to determine antiprotozoal selectivity [78]. Since some of the compounds synthesized were 
almost two orders of magnitude more highly cytotoxic than aculetatin A (3), then it would seem logical to 
screen this compound and its analogs against leukemia targets.  
Silvestrol and episilvestrol from Aglaia foveolata  
Our collaborative group has investigated the fruits and twigs of Aglaia foveolata Pannell (Meliaceae; originally 
misidentified as Aglaia silvestris), collected in Kalimantan, Indonesia, initially as part of our former NCDDG 
project [79]. (-)-Silvestrol (7; Fig. 2), a rocaglate derivative (flavagline) with an unusual pendant dioxanyl ring 
at C-6, was isolated from both the fruits and twigs of A. foveolata by bioassay-guided fractionation, and its 
structure and absolute stereochemistry determined by spectroscopic data interpretation and by X-ray 
crystallography [79]. Rocaglate derivatives from Aglaia species are known to be toxic to insects and cancerous 
mammalian cells [80,81]. These cyclopenta[b]benzofurans inhibit protein synthesis and induce cell cycle arrest 
in the G2/M-phase [82-84] and are potent and specific inhibitors of tumor necrosis factor alpha (TNFa) and 
phorbol 12-myristate 13-acetate (PMA)-induced NF-[kappa]B activity in human T cells [85]. Thus, silvestrol 
(7) was shown to be highly cytotoxic against a panel of human cell lines derived from breast, prostate, and lung 
cancers. The potency of silvestrol ([ED.sub.50] 1.2-1.5 nM) was similar to those observed for paclitaxel 
([ED.sub.50] 0.7-4.7 nM) and camptothecin ([ED.sub.50] = 30 nM). (+)-Episilvestrol (8; Fig. 2), the C-5"' 
epimer of silvestrol, was isolated and characterized as a minor component of A. foveoleata twigs, and found to 
be about three-fold less active as a cytotoxic agent than silvestrol [79]. In turn, silvestrol was over two orders of 
magnitude more potent as a cytotoxic agent than its analog, methyl rocaglate (9; Fig. 2), isolated in our previous 
work on Aglaia rubiginosa (Hiern) Pannell [79,86]. Compound 9 differs structurally from silvestrol (7) only by 
the substitution of the functionalized dioxanyl ring of the latter compound at C-6 with a methoxy group at this 
same position.  
These in vitro studies were followed by analysis of silvestrol (7) in vivo [79]. When silvestrol was tested in the 
hollow fiber assay at the University of Illinois at Chicago at doses up to 5 mg/kg, silvestrol inhibited 
proliferation of all cell lines, particularly the LNCaP human prostate cancer line (up to 83 % inhibition with ip 
administration), showing no detectable gross toxicity to the mice [79]. Silvestrol was also tested in the P388 
murine lymphocytic leukemia model at Bristol-Myers Squibb and found to be active at its maximum tolerated 
dose of 2.5 mg/kg when administered as five daily ip injections. A maximum increase in lifespan corresponding 
to a T/C ratio of 150 % was achieved. When silvestrol was injected intravenously twice daily for five days in 
the P388 model, a T/C ratio of 129 % was obtained at a cumulative dose of 2 mg/kg/day [79].  
Two cytotoxic and antineoplastic compounds with the same NMR spectroscopic properties as silvestrol and 
episilvestrol have been reported in the patent literature from the bark of a Malaysian plant, Aglaia leptantha 
Miq., with one of the compounds found to inhibit the growth of PC3 human prostate cancer cells in a xenograft 
study [87]. However, the inventors did not assign the full stereochemistry to either of these compounds. Very 
recently, (-)-silvestrol has been totally synthesized by the Porco and Rizzacasa groups [88,89]. In follow-up 
phytochemical work conducted recently at The Ohio State University, silvestrol (7) was found to occur in the 
leaves of A. foveolata collected in Indonesia, so that this plant part could be used as a renewable resource for 
the production of silvestrol, in the event this compound continues to show promise [90].  
At the University of Illinois at Chicago, studies have been conducted to elucidate the cellular mechanism of 
action of silvestrol (7) in LNCaP cells. It was revealed by microarray analysis of the molecular signature 
induced in cultured LNCaP cells by silvestrol that 20 apoptosis and cell cycle related genes were significantly 
altered [91]. Up-regulated genes included p21 (a potent cyclin-dependent kinase inhibitor that is governed by 
p53), and p300 (a transcription factor co-regulator). Compound 7 was found to down-regulate p53 at the RNA 
and protein level within 15 min of exposure, and, within 6 h of silvestrol exposure, no p53 could be detected by 
immunoblot. Also observed was down-regulation of MDM2, the E3 ligase specific for p53, which was not 
prevented by lactacystin, suggesting that silvestrol- induced degradation of p53 is not mediated by the 
proteasome. Cell cycle analysis by flow cytometry demonstrated that silvestrol induces a block in the cycle at 
the [G.sub.2]/M checkpoint [91].  
Moreover, cell-cycle arrest induced by silvestrol (7) led to cell death by apoptosis [92]. A follow-up 
investigation at the University of Illinois at Chicago on the mechanism of apoptosis induction in LNCaP cells 
revealed that silvestrol disrupted the mitochondrial trans-membrane potential and caused cytochrome c release 
into the cytoplasm. Compound 7 produced an increase of Bcl-xl phosphorylation and increased Bak expression. 
Caspases-2, -9, and -10 were demonstrated to be involved in silvestrol-mediated apoptosis, while caspases-3 
and -7 were not. Experiments using various cell-permeable inhibitors showed that only the general caspase 
inhibitor Boc-D-Fmk inhibited the formation of apoptotic bodies completely. This suggests that silvestrol 
induces the apoptosome/mitochondrial pathway to stimulate apoptosis in treated LNCaP cells [92].  
Pelletier and colleagues have shown recently that silvestrol (7) can inhibit translation in eukaryotic cells and 
enhance the sensitivity of lymphoma cells to doxorubicin [93]. The eukaryotic translation initiation factor (eIF) 
4F is a complex that stimulates ribosome recruitment to mRNA. Silvestrol targets eIF4A to prevent its 
association with eIF4FE and eIF4FG, thus preventing the formation of the eIF4F complex and subsequent 
translation. These findings suggest a novel mechanism for the antitumor activity of silvestrol [93].  
Recent studies by Grever and Lucas at The Ohio State University Medical Center, outside the scope of our 
current program project, have suggested that the cytotoxicity of silvestrol (7) is selective for B cells relative to T 
cells [94,95]. In their work, silvestrol was found initially to be selectively cytotoxic for chronic lymphocytic 
leukemia (CLL) cells relative to normal peripheral blood monocyte cells, with its cell killing independent of 
two key resistance factors, p53 and Bcl-2 [94]. The B-cell-specific activity was observed both ex vivo and in 
vivo using the Tcl-1 transgenic murine model of CLL. Silvestrol significantly decreased leukemic B cells in 
vivo, without detectable effects on T cell count. Silvestrol caused a rapid proteasome-independent reduction in 
Mcl-1 protein, which is a member of the Bcl-2 family of proteins associated with the outer mitochondrial 
membrane [95]. In October 2007, the Drug Development Group of the U.S. National Cancer Institute selected 
silvestrol for preclinical evaluation at the IIA level (including additional sourcing of the plant of origin and 
preliminary formulation, pharmacokinetics, and toxicology), potentially leading to clinical development.  
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